Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
| Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
| Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03513705 -
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
|
N/A | |
| Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
| Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
| Recruiting |
NCT02817308 -
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
|
N/A | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
| Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
| Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
| Completed |
NCT02150746 -
Circulating Tumor Cells in Operative Blood
|
N/A | |
| Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05621824 -
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
|